← 返回

血浆 EB 病毒 DNA 相较于外周血单个核细胞在监测 EBV 阳性 NK 细胞淋巴增殖性疾病中的优势

英文原题:The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.

查看英文原题

The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.

PubMed 2022/04/22(内容时间) Hematol Oncol Q1 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

EBV是一种无处不在的病毒,能够感染NK细胞并导致NK细胞型EBV阳性淋巴增殖性疾病(EBV-NK-LPDs)。我们回顾性分析了202例EBV-NK-LPDs患者(包括64例CAEBV-NK、27例侵袭性NK细胞白血病(ANKL)和111例结外NK/T细胞淋巴瘤(ENKTL))的EBV DNA拷贝数实验室检测结果与临床特征之间的关系。在CAEBV-NK队列中,血浆或PBMCs中的EBV DNA载量在活动期与非活动期之间具有显著差异。采用受试者工作特征曲线评估EBV DNA拷贝数的诊断准确性。比较曲线下面积后,血浆中EBV DNA载量在区分疾病活动方面的准确性显著高于PBMCs。

因此,我们提出将CAEBV-NK的诊断标准重新定义为血浆中EBV DNA拷贝数升高(超过7.1 10 2 copies/ml),而非外周血中。在ANKL和ENKTL队列中,接受有效治疗的患者血浆和PBMCs中的EBV DNA拷贝数显著低于治疗无效的患者。这种显著且一致的下降表明,血浆中EBV DNA载量是监测EBV-NK-LPDs治疗反应更为敏感的biomarker。噬血细胞性淋巴组织细胞增生症(HLH)可继发于EBV-NK-LPDs,多与不良预后相关,因此我们尝试通过监测EBV DNA拷贝数来评估HLH的合并情况。比较EBV DNA拷贝数的受试者工作特征曲线时,血浆中EBV DNA载量具有更高的诊断准确性。当拷贝数水平超过4.16 10 3 copies/ml时,可能提示合并HLH。

展开英文摘要原文

Epstein-Barr virus (EBV), characterized as an omnipresent virus, has been found able to infect NK cells and leads to NK-cell type EBV-positive lymphoproliferative diseases (EBV-NK-LPDs).

We retrospective analyzed 202 EBV-NK-LPDs (including 64 CAEBV-NK, 27 aggressive natural killer-cell leukemia (ANKL), and 111 extranodal NK/T-cell lymphoma (ENKTL)) patients' relationships between EBV DNA copies laboratory test results and clinical features.

In CAEBV-NK cohort, EBV DNA loads in either plasma or PBMCs had significant differences between the active state and the inactive state. Receiver operating characteristic curves were used to measure the diagnosis accuracy of EBV DNA copies. After comparing the area under the curve, EBV DNA loads in plasma had significantly higher accuracy in distinguishing disease activation than in PBMCs.

Therefore, we propose redefining CAEBV-NK diagnosis criteria as increased EBV DNA copies in plasma (over 7. 1 10 2 copies/ml) instead of in peripheral blood. In ANKL and ENKTL cohorts, patients who received effective therapy had significantly lower EBV DNA copies in plasma & PBMCs than in those with ineffective therapy. The significant and consistent decline indicated EBV DNA loads in plasma being a more sensitive biomarker in monitoring EBV-NK-LPDs therapy responses.

Hemophagocytic lymphohistiocytosis (HLH) can occur secondary to EBV-NK-LPDs, mostly associated with a poor prognosis, so we try to estimate the combination of HLH by monitoring EBV DNA copies. When comparing the Receiver operating characteristic curves of EBV DNA copies, EBV DNA loads in plasma had higher diagnosis accuracy. When the copies level over 4. 16 10 3 copies/ml, it might indicate combining with HLH.

论文信息

作者
Zheng M、Bao Y、Wang J、Ma Y、Yang Y、Zhang P、Chen L、Zheng K
单位
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
期刊
Hematological oncology2022 Aug
原文标识
PubMed 35405763 · DOI 10.1002/hon.2998